Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Add as a preferred source on Google
REDWOOD CITY, Calif., May 01, 2018 -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the Company will report first quarter 2018 financial results and operational highlights on Tuesday, May 8th, 2018. OncoMed will not be conducting a conference call in conjunction with this earnings release.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. Anti-TIGIT (OMP-313M32), navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), and rosmantuzumab (anti-RSPO3, OMP-131R10) are part of OncoMed's strategic alliance with Celgene Corporation. OncoMed is independently developing GITRL-Fc (OMP-336B11), as well as continuing to pursue new drug discovery research. For further information about OncoMed Pharmaceuticals, please see www.oncomed.com.
Investor Relations Contact:
Matthew Beck
Solebury Trout
[email protected]
(646) 378-2933
